Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that focuses on developing differentiated oral products utilizing its pharmaceutical technologies, has announced its co-sponsorship of the Controlled Release Society’s Young Investigator Award and its participation in the 39th Annual Meeting & Exposition of the Controlled Release Society, which will take place 15-18 July 2012 in Québec City, Canada.
2012 CRS Young Investigator Award
Aptalis Pharmaceutical Technologies, co-sponsor of the 2012 CRS Young Investigator Award, joins the Controlled Release Society in recognizing Cory Berkland, MS, PhD as the recipient of the 2012 CRS Young Investigator Award at the Society’s Annual Meeting & Exposition.
Dr. Berkland is a professor in the Department of Chemical and Petroleum Engineering and in the Department of Pharmaceutical Chemistry at the University of Kansas, US. He received MS and PhD degrees from the Department of Chemical and Biomolecular Engineering at the University of Illinois at Urbana-Champaign and a BS degree in chemical engineering from Iowa State University in Ames. His lab studies colloids, polymers, and biomaterials. Professor Berkland is a co-founder of Orbis Biosciences and Savara Pharmaceuticals.
The Young Investigator’s Award recognizes a CRS member who has made outstanding contributions in the science of controlled release and is 40 years of age or younger on 31 December 2011.
CRS Annual Meeting & Exposition
Aptalis Pharmaceutical Technologies’ two poster presentations, conducted in collaboration with the University of Genova, Italy, are:
- A Hydrophilic Matrix Generated by Direct Compression and Thermal Treatment: Application in Press-Coating. Poster session #2, Tuesday 17 July, 9.30am – 10.30am at Poster Board #480
- A New Hydrophilic Bioadhesive Matrix for Controlled Drug Release Generated In Direct Compression Tablets by Thermal Treatment: Mechanism Elucidation. Poster session #3, Tuesday 17 July, 3.00pm – 4.00pm at Poster Board #481
Meeting participants are invited to visit Aptalis Pharmaceutical Technologies at booth #209 and attend the above poster presentations.